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ARTICLE HIGHLIGHTS 
 
 Recent advances in structural and biophysical characterization of GPCRs lead to 
improved efficacy of in vitro and in silico fragment-based lead discovery for 
GPCRs 
 Virtual fragment screening is a feasible approach for GPCR lead discovery 
 Multiple receptor conformations (including both experimental and theoretical 
models) might enhance the success rate of virtual fragment screening 
 Relevance of biophysical methods for fragment screening and evaluation on 
GPCRs has increased significantly 
 In vitro biological assays are suitable for functional screening on GPCRs 
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ABSTRACT 
 
Introduction 
G-protein-coupled receptors form one of the largest groups of potential targets for novel 
medications. Low druggability of many GPCR targets and inefficient sampling of chemical 
space in high throughput screening expertise however often hinder discovery of drug 
discovery leads for GPCRs. Fragment-based drug discovery is an alternative approach to the 
conventional strategy and has proven its efficiency on several enzyme targets. Based on 
developments in biophysical screening techniques, receptor stabilization and in vitro assays, 
virtual and experimental fragment screening and fragment-based lead discovery recently 
became applicable for GPCR targets. 
 
Areas covered 
Biophysical as well as biological detection techniques suitable to study GPCRs are reviewed, 
together with their applications to screen fragment libraries and identify fragment-size ligands 
of cell surface receptors. Several recent examples are presented, including both virtual and 
experimental protocols for fragment hit discovery and early hit to lead progress. 
 
Expert opinion 
With the recent progress in biophysical detection techniques the advantages of fragment-
based drug discovery could be exploited for GPCR targets. Structural information on GPCRs 
will be more abundantly available for early stages of drug discovery projects, providing 
information on the binding process and efficiently supporting the progression of fragment hit 
to lead. In silico approaches in combination with biological assays can be used to address 
structurally challenging GPCRs and confirm biological relevance of interaction early in the 
drug discovery project. 
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1. INTRODUCTION 
 
The superfamily of G-protein-coupled receptors (GPCRs) consists of a large number of 
potential drug targets and their role in numerous diseases has been proposed (1). Discovery of 
suitable drug candidates targeting specific GPCRs has been often hindered by various factors 
like achieving sufficient potency and selectivity and lead to numerous failures in this target 
class (2). In one hand, a number of technical challenges encumbered the experimental 
investigation of their atomic level structure (3-4) that limits the success of their in silico 
targeting. On the other hand, dynamic intramolecular organization (5) of these receptors lends 
high degree of complexity between ligand binding and functional efficacy and phenomena 
like signalling bias (6-8). Despite these difficulties, GPCRs represent a family with high 
potential to serve as targets of novel pharmaceutical agents. 
 
Fragment-based drug discovery has proven as an efficient approach as demonstrated on 
various enzyme targets (5). The basic concept of this paradigm lies in identification of 
efficiently binding low molecular weight fragments of druglike structures to serve as starting 
points for lead discovery. This way a more efficient sampling of chemical space is possible in 
addition to exploring and enthalpy-lead targeting of protein “hot spots” (10) expected to result 
in higher developmental potential for fragment-derived ligands. Although fragment-based 
drug discovery in the last decade has lead to several clinical candidates on enzyme targets, its 
utility for integral membrane proteins has been regarded limited. Recently, significant 
advance has been achieved in structural investigation methods of GPCRs as well as receptor 
stabilization and presentation techniques required for development of screening assays (11). 
Several very recent reports for as diverse techniques as NMR screening on immobilized 
receptors (12) to live cell binding studies (13) with the aim to identify and develop fragment-
size GPCR ligands have been reported. It is expected that wide spread application of 
fragment-based drug discovery to GPCR targets could provide novel chemical matter 
previously inaccessible for random screening. 
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2. FRAGMENT HIT DISCOVERY ON GPCRS 
 
2.1 Virtual screening 
Virtual screening has become an industry standard for the identification of chemical starting 
points for a wide variety of targets. Although ligand-based methods were found to be useful 
for structurally not characterized targets high throughput docking is clearly the most popular 
approach used in structure based virtual screening (14). The success of such a screen basically 
depends on multiple factors including the accuracy of the protein structure used for docking, 
the docking algorithm and the scoring function used for the prediction of binding mode and 
energetics, and also the characteristics of the library screened.  
Protein structures might be available from both experimental and theoretical sources. 
Experimental structures are usually better suited for virtual screening; however, the flexibility 
of the protein is often considered using theoretical approaches such as docking to 
conformational ensembles typically generated by molecular dynamics simulations (15). 
Comparative modeling represents another option for targets having sequential homologues 
with known 3D structure. Although homology models were used successfully in a number of 
cases their usefulness depends strongly on the level of sequence identity and the character of 
the target (16). The limited availability of experimental GPCR structures made homology 
models popular for virtual screening applications. On the other hand, however, recent 
developments in GPCR structural biology resulted in a high number of GPCR structures 
initiating a significant number of virtual screening studies (18-22). Fast and often parallelized 
docking algorithms allow the prediction of the binding mode for hundreds of thousands of 
potential ligands in reasonable time. There are, however, several limitations of these 
approaches since (i) they are typically neglecting the flexibility of the protein that limits the 
accuracy of the pose prediction and (ii) they estimate the binding affinity by empirical scoring 
functions that limit the accuracy of ranking docked ligands. In general, proteins with limited 
flexibility are better suited for virtual screening studies. Membrane proteins, such as GPCRs 
might therefore be advantageous in virtual screening applications. It is interesting to see that 
the most popular docking tools show pretty similar performance on different target classes 
(23) scoring functions should be optimized or even tailored for the actual problem.  
The character of the screened ligands might also influence the outcome of virtual screening. 
In routine applications typically druglike libraries are screened virtually. More recently, 
however, fragment based approaches seem to be more and more popular in the virtual world 
that is indicated by the increasing number of virtual fragment screens reported (24-25). There 
are, however, a number of challenges associated to these applications. First, fragments are 
small and polar compounds that might interact with a relatively large number of interaction 
sites on the protein surface. Second, small volume of fragments relative to that of the binding 
site could result multiple alternative binding modes or even incorrect poses. Third, estimation 
of their binding affinity might be less accurate since (i) most of the scoring functions are 
optimized for druglike compounds (ii) fragments form less interactions with the target that are 
more challenging to estimate. Despite of these factors virtual fragment screening is a viable 
alternative of experimental approaches if the experimental structure of the target is available. 
In this special case low resolution homology models are less feasible since poses of small 
fragments could only be estimated with relatively large errors that impacts the screening 
efficacy negatively.  
In the next section we review several case studies on virtual fragment screening against 
GPCRs that includes histamine, adenosine and dopamine receptors. Here we discuss the 
impact of experimental structures and homology models as well as screening on active and 
inactive receptor conformations. 
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2.1.1. H1 antagonist screening 
One of the first published virtual fragment screening has been performed on the recently 
available X-ray structure of the human histamine H1 receptor (26). The authors started from 
757,728 fragment like compounds with less than 22 non-hydrogen atoms and generated 
plausible tautomers and protonation states. Next they selected only those carrying a formal 
charge of +1  (108,790 fragments) ensuring that these fragments might form ionic interactions 
with the crucial and highly conserved D107 residue located in helix 3. Then these fragments 
were docked to the binding pocket of hH1 receptor by the docking program PLANTS. 
Fragments with binding modes contacting to D107 were considered further (95,147). These 
poses were post-processed by interaction fingerprints generated from the interactions 
identified for doxepine co-crystallized with hH1 receptor. The resulted 354 fragments were 
first subjected to the Tanimoto based novelty filter that compares the virtual hits to known 
hH1 antagonists. The last round of visual inspection gave 30 fragments from which 26 were 
available for experimental testing. Interestingly, 19 fragments showed hH1 affinity in the 
range of 10 M to 6 nM resulting in an exceptionally high hit rate of 73%.  
 
2.1.2. H3 antagonist 
In addition to structure-based methods ligand-based approaches might also be useful 
identifying reduced complexity low molecular weight starting points. In a recent paper Sirci 
and coworkers reported the identification of new histamine H3 receptor antagonist fragments 
using ligand-based and protein-based molecular fingerprints (27). Their methodology termed 
as FLAP (Fingerprint for Ligands And Protein) first identifies 4-point pharmacophores by 
interacting molecular fields (MIFs) that are used to align the compounds with specific 
biological activity. In the final step linear discrimination analysis (LDA) is used to generate 
probe scores discriminating compounds with different affinity. This approach has been tested 
against conventional ligand-based and structure-based virtual screening. In a retrospective 
study FLAP outperformed both Tanimoto ECFP-4 similarity, ROCS shape similarity and also 
docking methods including PLANTS and GOLD, for virtually all test set compounds. These 
positive results prompted the authors to screen 156,090 fragment-like compounds collected 
from ZINC by FLAP. LDA-R scores calculated for both ligand-based and structure-based 
FLAP approaches gave 1,292 and 28,973 fragments with probe score larger than 0.5. The 
authors then selected the 202 consensus hits and also the top 200 fragments identified by the 
ligand-based FLAP approach. After visual inspection 29 of them were selected and measured 
to yield 19 compounds (63%) with H3 affinity between 0.5 and 10 M as measured in a 
radioligand binding assay.  
 
2.1.3. H3/H4 antagonist 
A combined approach using both ligand and protein information has been published by 
Evotec (28). First the structure of the human histamine H3 receptor was modeled using 
comparative modeling, next the binding pocket was optimized by fully flexible docking of 
known H3 ligands. This resulted in bioactive conformations for druglike H3 compounds that 
were used in a subsequent ROCS shape similarity search performed on 4 million compounds. 
Results of experimental fragment screening served as an alternative source of ROCS queries 
using both H3 specific and dual H3/H4 fragment hits. ROCS searches provided 2500 primary 
hits from each type of queries that were finally docked into the optimized binding pocket of 
the H3 homology model. Best scored virtual hits have been visually inspected and 62 of them 
have been selected for biological testing. 
In parallel the authors developed a homology model for the human histamine H4 receptor that 
was further optimized using H4 selective fragment hits. Dual H3/H4 and H4 specific fragment 
hits were then docked into the optimized binding site to obtain bioactive conformations for 
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the subsequent ROCS shape similarity search that identified 1200 virtual hits for each type of 
queries. This set of hits was extended by further 12,000 compounds identified by searching 
known 2D H4 substructures in the database of 4.8 million compounds. The total of 14,400 
primary hits was then docked into the optimized binding pocket of the H4 homology model. 
Best scored virtual hits have been visually inspected and 110 of them have been selected and 
combined with the previously identified 62 H3 hits for biological testing. The total of 172 
H3/H4 hits were evaluated at 20 M concentration in functional tests on histamine H3 and H4 
receptors providing 79 (54%) and 58 (40%) hits, respectively. 
 
2.1.4. H4 antagonist 
As a continuation of our work aiming to identify novel chemotypes for the H4 receptor (29) 
we developed a molecular dynamics-based protocol for virtual fragment screening. We first 
created a homology model for the human H4 receptor and its complex with JNJ7777120 was 
subjected to explicit membrane simulations with TIP3P waters in NAMD 2.7. After 20 ns 
NpT equilibration at 310 K we run five independent 5 ns long NpT simulations and the 
resulting trajectories were analyzed to identify structurally diverse frames for fragment 
docking. Frame selection was based on the calculation of RMSD values for the interacting 
residues around the JNJ7777120 ligand. RMSD based clustering by average linkage 
methodology provided 12 frames in total that were used for virtual fragment screening. 
Comparing the results provided by docking to MD frames with that obtained by the homology 
model-based virtual screening we concluded that virtual screening of 13,000 fragments gave 8 
and 5 hits with larger than 20% displacement at 10 M (30). These results revealed that MD 
based ensemble approach provides much higher enrichment (20%) that that of the single 
structure screen (11%). 
 
2.1.5. D3 antagonist 
A similar MD based strategy has been applied to human D3 receptor having an X-ray structure 
available for virtual screening. Docking the 13,000 fragments to the experimental structure 
yielded 9 hits with displacement larger than 20% as measured at 10 M that gave the hit rate 
of 18%. Contrary, docking the same set of fragments to 29 frames identified by the analysis of 
MD trajectories resulted in 18 hits in total having displacement larger than 20% at 10 M 
yielding the hit rate of 32% (31). Again, this study demonstrated that MD based ensembles 
might provide better enrichment than single structure virtual fragment screening. 
 
2.1.6. A2A agonist 
Despite the fact that most of the available GPCR structures are in inactive state several 
screening programs aim the identification of activators. Successful virtual screening for 
agonists typically requires active state conformations. The high resolution structure of the 
activated adenosine A2A receptor provided a new opportunity for virtual agonist screening and 
structure-based fragment design (32). The authors compared the performance of virtual 
screening on three different receptor conformations including the active and inactive X-ray 
structures and an agonist optimized model. The screening library consists of substituted 
adenosine derivatives, 10 derivatives with known active substituent available from ChEMBL 
and further 200 derivatives as decoys. Decoys were generally low molecular weight fragments 
(MW<130) from commercial databases. It was rather obvious that the activated experimental 
structure provided the best enrichment of AUC=93%. Screening efficacy on the inactive 
experimental structure was much inferior (AUC=57%), and finally the agonist-optimized 
inactive model served as an intermediate source of new fragment chemotypes. This study 
indicates that virtual fragment screening for agonists is not an easy task. Enrichment factors 
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are typically higher for active receptor conformations from which experimental structures 
might be somewhat better relative to agonist optimized inactive conformations. 
 
 
2.2. Biophysical screening 
The major obstacles of applying fragment-based drug discovery are specific identification of 
substantially lower affinity on-target interactions and assessment of development propensity 
of low complexity hits. Thus, in contrast to conventional drug discovery often carried out 
based on indirect evidence, fragment-based approach is seriously limited in lack of direct 
observation of interactions with the molecular target. NMR spectroscopy as well as X-ray 
crystallography allow for direct and sensitive detection of ligand-target interaction less prone 
to downstream artifacts of detection (33), but historically GPCRs, just like other membrane 
targets, fell out of scope of structure-based approaches. Owing to very recent achievements in 
stabilization techniques of membrane proteins as well as direct detection methods to monitor 
low affinity interactions GPCRs became accessible for biophysical detection techniques 
(12,34). The advent of this approach was demonstrated by successful structure-based drug 
discovery on a GPCR under industrial settings (35). Not only more refractory to downstream 
signal interference compared to biological assays, biophysical techniques in theory could 
provide structural or kinetic information on ligand binding that could contribute to efficient 
hit validation and evaluation. In the subsequent sections, recent applications of biophysical 
detection techniques in fragment screening on GPCRs and hit to lead transition are presented. 
 
2.2.1. Nuclear magnetic resonance spectroscopy 
Capable to detecting both orthosteric and allosteric binding events of loosely bound ligands, 
ligand-observed 
1
H NMR spectroscopy techniques like saturation transfer difference (STD) 
(36) or waterLOGSY (37) proved powerful in the study of protein-ligand interactions (38). 
However, owing to the surface transfer of proton resonances, these methods are sensitive to 
aggregation and nonspecific binding, and thus, their utility diminish when studying complex 
heterogeneous systems like membrane protein preparations. Target immobilized NMR 
screening (TINS) (39) overcomes this problem by utilizing flow-injection NMR spectroscopy 
on immobilized protein preparations in a dual cell sample holder with spatially selective 
detection. Elimination of signals originating from nonspecific binding is achieved by 
subtraction of the 
1
H spectrum of the reference channel which contains preparation of a 
protein with low druggability. In addition to the resulting improved specificity, also lower 
protein consumption and sensitivity of TINS are favorable compared to traditional 
1
H NMR 
methods (40). Successful application of the technique for GPCRs has been reported with 
stabilized β1 (12) and A2A receptors (41), where signals from a preparation of the rather 
nondruggable OmpA protein served for correction of nonspecific binding. In these proof-of 
concept studies, 579 and 531-membered libraries, respectively, were screened as 3-8 
component mixtures at 500 µM. A rather conservative hit selection resulted in hit rates of 
18% and 14% respectively, and more than 10 fragment hits in each case (ca. 2% overall hit 
rate) whose binding could be confirmed using a biochemical assay. As detailed investigation 
of screening hits for A2A revealed, both orthosteric and allosteric ligands were identified using 
the TINS method, the latter ones characterized by higher selectivity over close homologue A1 
(41). 
Although the SAR by NMR principle by 2D protein-observed NMR was developed especially 
for fragment-based lead discovery (42), routine use of 
15
N or 
13
C correlated NMR 
spectroscopy is limited due to deconvolution of complex 2D spectra and resource intensive 
isotope-labeling of the protein sample, the limit for which currently lies near the size of 
GPCRs. Although this approach currently falls out of reach for primary fragment screening 
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for GPCRs, liquid phase protein NMR spectroscopy could in the future support studying 
conformational or dynamic changes of the receptor upon ligand binding without the need for 
immobilization (43). 
 
2.2.2. X-ray crystallography 
Around 2007, a breakthrough in crystallographic investigation GPCR structure and function 
has been achieved, enabled by advanced protein isolation and stabilization techniques in 
addition to availability of improved X-ray sources, culminating in resolving the crystal 
structures of numerous GPCRs as well as illuminating various phases of the receptor 
activation cycle (44-45). For crystallization purposes, receptor stabilization is achieved either 
by fusion with a highly crystallizable protein, like T4 bacteriophage lysozyme, addition of a 
stabilizing antibody or site-directed mutations (11). Although the approach is very 
informative on determining binding mode of an actual fragment hit, various limitations are 
also obvious for this method to be used in mass screening. Crystal soaking with ligands 
provides an approach more suited for screening studies, where however, crystal packing or the 
crystallized conformation of the receptor might hinder proper binding to occur (46). 
Moreover, high resolution structural determination of low affinity ligands, more stable 
receptors might be required compared to alternative biophysical techniques (47), 
demonstrated by the co-crystallization of several leadlike compounds with the adenosine A2A 
receptor (48, see latter). X-ray crystallography on GPCR targets could in the near future serve 
as a powerful tool to validate and evaluate screening hits on GPCRs and provide valuable 
support in efficient elaboration of fragment hits. 
 
2.2.3. Surface plasmon resonance 
Binding of GPCR ligands to receptors attached to biosensors was detected by surface plasmon 
resonance for tagged wildtype (49) as well as stabilized receptors (50). Captured onto 
antibody or NTA surfaces of a sensor chip, purified proteins or even crude extracts could be 
applied for detecting small molecule binding (50). Although ligand mass-dependent effect 
size hints at potential limitations of SPR for fragment screening (51), Congreve et al. 
successfully screened a library of 136-194-Da fragments on an A2A receptor construct 
stabilized in the antagonist mode (12). A hit rate of 10% was achieved at a screening 
concentration of 200 µM and binding affinity as low as 5 mM could be detected, 
demonstrating the utility of SPR for primary screening of weak ligands. Moreover, this 
technique allows for experiments to be run in multiple formats, capable to extract both 
equilibrium and kinetic data on the binding event. 
 
2.3. Biological screening assays 
Irrespectively of primary screening strategy, high concentration biochemical assays are 
regularly used in the secondary phase of fragment-based drug discovery projects. Their utility 
is warranted by the need to demonstrate biological relevance of the binding event before 
initializing an extensive and demanding chemistry program for lead identification. However, 
apart from fulfilling this supportive role, traditional in vitro biological assays also offer an 
easily accessible repertoire for screening fragment libraries at high concentration. In addition 
to the relative ease of application a further benefit is the quantitative data acquired, as 
fragment hit evaluation relies more on calculated ligand efficiency than on absolute activity 
(52). Lastly, GPCRs are known to adopt multiple active conformations that might bear 
therapeutic relevance from a drug discovery perspective (4, 53). Biochemical assays 
presenting the target in a dynamic fashion and in proper supramolecular context might thus 
also support fragment screening against membrane targets. 
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2.3.1. Binding assays 
High concentration screening of fragment libraries against GPCR targets can be performed 
utilizing in vitro biochemical assays developed for conventional drug discovery programs. As 
an example, researchers from AstraZeneca reported discovery of melanocortin 4 receptor 
ligands using a radioligand binding assay (54). Screening at 1 mM concentration resulted in 
9% hit rate, followed by rapid hit expansion on druglike derivatives of fragment hits. 
Fragment screening of several histamine receptors subtypes and adrenergic β2 receptor using 
radioligand has been reported (55, 56). The somewhat low test concentration in the binding 
assays (10 µM) was justified by the 0.4-6% hit rate on the particular library. Contradictory to 
expectations on fragment binding, lower level of selectivity has been observed among more 
complex fragment hits, a phenomenon that could not be explained based upon sequence 
homology. 
Finally, an interesting approach utilizing a fluorescent ligand of adenosine A3 receptor was 
reported recently, where fluorescence intensity of a xanthine amine congener analogue 
reported on binding to intact cells (13).  Fragment screening was performed on a high content 
imaging platform and resulted in 15% hit rate with activity as low as pKi=3.97 reliably 
detected. Not confined to high content instrumentation, this live cell approach could in theory 
be pursued with time-resolved fluorescence spectroscopy, fluorescence anisotropy or 
fluorescence correlation spectroscopy (FCS) as well. 
 
2.3.2. Functional assays 
The interaction of the relatively featureless interfaces CXCR4 and CXCL12 has proved 
challenging to target using conventional drug discovery tools. Mysinger and colleagues 
reported a virtual screening-based approach, followed by high concentration testing of hits in 
a functional assay (20). In this case leadlike (logP<3.5, molar weight<350 Da, number of 
rotatable bonds<8) compounds were virtually screened followed by testing hits at high 
concentration (100 µM) in a calcium mobilization and subsequently in a cell migration assay. 
Several hits displayed activity in both in vitro models with no sign of acute toxicity assessed 
via Trypan Blue exclusion (20). Interestingly, when assessed for binding activity, two of the 
five hits lacked the ability to displace labeled CXCL12, emphasizing at the complexity of the 
chemokine-receptor interaction. 
The first reported functional agonist fragment screen has been presented by Szőllősi and 
colleagues on adrenergic α2c receptor (57). High concentration screening of more than 3000 
fragment-sized compounds using a calcium assay lead to the identification of 16 validated 
fragment hits, several of which displayed submicromolar affinity and micromolar potency. 
Counterscreening in this case was performed using a non-related target, however, owing to 
the lower specificity of fragment hits versus druglike compounds (58), this approach might 
have underestimated specificity of actives. Similar to the above example, however, no strong 
correlation between agonist potency and binding affinity could be observed, as several close 
neighbors of agonist fragment hits turned out to act as potent antagonists of α2c receptor. 
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3. FOLLOW UP OF HITS 
Owing to necessarily multicomponent preparations of GPCRs in a hydrophobic environment 
and the usually low affinity of fragment hits, validation of hits is crucial as the first step in hit 
to lead activity. Biophysical screening hits can turn out to be nonspecific aggregators (38, 59) 
or intractably low affinity binders, while biological screening assays are prone to be misled by 
assay interference or poor solubility (60). Typically, demonstration of target specific or direct 
interaction as well as pharmacologically relevant binding should be required for an active to 
qualify as a true hit. Selectivity, although not impossible to obtain, is not a requirement at the 
fragment hit level (61), thus counterscreening low complexity hits using a homologous target 
should be used in extreme situations only. 
 
It is unequivocal that evaluation of developmental potential of fragment hits can be more 
adequately assessed based on ligand binding efficiency than absolute affinity (e.g. 52). 
Multiple approaches are available to pursue a particular fragment hit (52), either by increasing 
ligand efficiency (hit optimization) or by increasing size at near constant ligand efficiency (hit 
evolution) (62). Hit expansion using fragment hits for substructure searching have resulted in 
several slightly more potent, but disproportionally less efficient ligands on MC4 receptor (54), 
not unlike results obtained after high concentration functional fragment screening against 
ASIC3 channel (63). Szőllősi et al. (57) reported adrenergic α2c agonist fragment hits, several 
size-matching neighbors of which behaved as more potent and more efficient ligands, albeit, 
as functional testing revealed, acting as antagonists of the target. This example underlines the 
importance of testing functional activity early on in the lead discovery process. 
Stoddart et al. report on a more successful case of fragment screening and early hit to lead 
activity on a GPCR target (13). Their initial screen using a live cell binding assays resulted in 
several highly efficient hits on the adenosine A3 receptor. After unsuccessful initial efforts on 
optimization of the most potent hit DP 01095 while maintaining low molecule size, careful 
and systematic hit evolution was undertaken. Small scale extension of the scaffold resulted in 
several analogues of higher potency and improved selectivity versus the main antitarget A1 
receptor and demonstrated thus, that careful elaboration of an initial fragment hit, although 
very demanding can be applied successfully for lead generation.  
 
Although not yet accessible for a generic GPCR target, X-ray crystallography can prove 
exceptionally effective for obtaining structural information about fragment binding. 
Crystallography was applied successfully in practice to complement biochemical and SPR 
data in discovery of A2A antagonists starting from virtual screening hits (48). At a crucial 
point of lead optimization, two fragment-size key compounds were crystallized with the 
receptor to gain valuable structural information on their binding mode and optimization 
potential. Eventually a close analogue displaying beneficial pharmacological properties, 
including long residence time at the receptor as measured with SPR was progressed into in 
vivo studies (48). This excellent piece of work showed that utilizing highly demanding 
biophysical approaches can indeed efficiently support lead generation on GPCRs (35). 
 
 11 
4. EXPERT OPINION 
 
Drugs targeting GPCRs form a substantial part of clinically successful therapeutic agents and 
this target class stills bears opportunities for drug discovery. In the past, however, many 
GPCR targets have been targeted in vain as suboptimal affinity or selectivity has hindered 
successful drug discovery (2, 64). It can be assumed that, in lack of structural information for 
in silico screening and insufficient coverage of chemical space for random in vitro screening, 
inefficient hit discovery might have contributed substantially to the failure of discovery 
efforts on promising GPCR targets. 
 
The paradigm of fragment-based drug discovery has proven its efficiency against soluble 
targets (9) and recent developments in biophysical investigational methods bear the promise 
to efficiently tackle membrane proteins as well. The major obstacle for application of a 
fragment-based approach to cell surface receptors lie in the difficulty to present an arbitrary 
GPCR ready for structural and biophysical studies, to sensitively and specifically identify 
fragment ligands and to efficiently evolve low complexity screening hits. Moreover, bridging 
binding phenomena to functional consequences like proper downstream signaling events or 
receptor modulation might be crucial to achieve pharmacological relevance. 
 
Although limited number of case studies has been reported, virtual fragment screening seems 
to be a promising approach for the identification of low complexity starting points for GPCR 
targets. Considering that the number of potential fragments with maximum 17 non-hydrogen 
atoms is still about 166 billion (65) virtual fragment screening might contribute to the design 
of screening libraries and would be useful prioritizing fragments for acquisition and 
screening. On the other hand, early results suggest that it might be a viable strategy for the 
identification of GPCR hits. Analyzing the experimental activity of virtual fragment hits we 
think that their potency is typically higher than that reported for other target classes. In fact, 
fragments identified for aminergic GPCR in the case studies reviewed here show micromolar 
potency. Since endogenous ligands of these receptors are also polar, low complexity 
compounds fragment hits fit well to their binding site of similar size and form interactions 
similar to natural ligands. Although scoring schemes designed for druglike compounds might 
limit the docking accuracy for fragments (17) these characteristic polar interactions formed at 
the hot spot seem to be adequately described. This is reflected in the unusually high hit rates 
reported for this subclass of GPCR targets. Although the binding cavity of peptidergic GPCRs 
and lipid receptors might also contains hot spots with similar characteristics we think that 
virtual fragment screening on these subclasses would provide lower hit rates. Virtual 
screening results obtained for druglike compounds are in line with this hypothesis (26) since 
hit rates for aminergic receptors are usually much higher than other GPCRs (20-40% vs. 0-
10%, respectively). Considering the relatively high hit rates found in the reviewed virtual 
fragment screens one consider this approach as a viable alternative for peptidergic GPCRs and 
lipid receptors. Based on these conclusions we argue that similar to the druglike situation 
integration of virtual and experimental fragment screening would be a synergistic approach 
for maximizing the output of fragment approaches applied for GPCR targets.  
 
Either after virtually screening a large library of potential binders or a moderate to small 
collection of real samples, experimental detection of protein-ligand interaction has to be 
demonstrated in vitro (Figure 1). Recently, successful examples have been reported for 
fragment screening against GPCR targets using surface plasmon resonance (12) and target 
immobilized NMR screening (12, 41). NMR screening is typically performed on mixtures and 
both methods can be run against libraries of several hundred to thousand samples and to 
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identify both orthosteric and allosteric ligands. Quality control for non plate-based fragment 
screening methods is not as standardized yet as for conventional in vitro assays, still, 
Congreve et al. included regularly a positive control at SPR testing to demonstrate 
reproducibility and stability of the assay (12). 
 
Lately, independently from 
1
H techniques, 
19
F NMR has been proposed as an efficient tool for 
fragment screening based on its high sensitivity and specificity suitable for screening mixtures 
(66). In theory, combination of TINS with 
19
F NMR spectroscopy could yield a method of 
improved throughput and detection sensitivity to be applied for screening reasonable size 
fragment libraries against GPCRs and other membrane targets. Yet another novel method, 
preliminary data on capillary electrophoresis point at the potential of upcoming developments 
of this analytical technique aiming at screening of fragment ligands (35). 
 
Conventional in vitro screening assays have been also reported for fragment screening on 
GPCRs and considering the pharmacological complexity of G-protein-coupled receptor 
function, these assays play a major role in a fragment or structure-based drug discovery 
program on a receptor target. Low specificity can indeed compromise data from high 
concentration biological testing, but this can be countered with novel more specific readouts 
of cellular events (e.g. 67). Although follow up of hits might prove challenging in lack of 
structural information (54), careful hit expansion on adenosine A3 receptor has demonstrated 
that biological testing can still form the basis for a fragment-based lead discovery approach 
(13). 
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Figure 1. Fragment based hit discovery for GPCRs 
 
